Interpace Biosciences Inc IPO-Jahr
Was ist das IPO-Jahr von Interpace Biosciences Inc?
IPO-Jahr von Interpace Biosciences Inc ist 1998
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Interpace Biosciences Inc
Was macht Interpace Biosciences Inc?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Unternehmen mit ipo-jahr ähnlich Interpace Biosciences Inc
- Rimfire Pacific Mining NL hat IPO-Jahr von 1997
- Flagstar hat IPO-Jahr von 1997
- Active PLC hat IPO-Jahr von 1997
- Redflex hat IPO-Jahr von 1997
- Norwest NL hat IPO-Jahr von 1997
- Kaleyra Inc hat IPO-Jahr von 1997
- Interpace Biosciences Inc hat IPO-Jahr von 1998
- Tuesday Morning hat IPO-Jahr von 1999
- American Axle & Manufacturing Inc hat IPO-Jahr von 1999
- Liontrust Asset Management Plc hat IPO-Jahr von 1999
- Empire Petroleum hat IPO-Jahr von 1999
- Surefire Resources NL hat IPO-Jahr von 1999
- NXT Solutions hat IPO-Jahr von 1999